Alnylam Pharmaceuticals Inc (ALNY)vsAmicus Therapeutics Inc (FOLD)
ALNY
Alnylam Pharmaceuticals Inc
$295.05
-0.29%
HEALTHCARE · Cap: $39.51B
FOLD
Amicus Therapeutics Inc
$14.49
0.00%
HEALTHCARE · Cap: $4.55B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 576% more annual revenue ($4.29B vs $634.21M). ALNY leads profitability with a 12.6% profit margin vs -4.3%. ALNY earns a higher WallStSmart Score of 65/100 (B-).
ALNY
Strong Buy65
out of 100
Grade: B-
FOLD
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.6%
Fair Value
$2410.60
Current Price
$295.05
$2115.55 discount
Intrinsic value data unavailable for FOLD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 90 in profit
Revenue surging 96.4% year-over-year
Growing faster than its price suggests
Strong operational efficiency at 23.0%
Revenue surging 23.7% year-over-year
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 36.6x book value
Trading at 16.5x book value
Elevated debt levels
Weak financial health signals
ROE of -11.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth, PEG Ratio. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.51 suggests the stock is reasonably priced for its growth.
Bull Case : FOLD
The strongest argument for FOLD centers on Revenue Growth. Revenue growth of 23.7% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 74.2x leaves little room for execution misses.
Bear Case : FOLD
The primary concerns for FOLD are Price/Book, Debt/Equity, Piotroski F-Score. Debt-to-equity of 1.61 is elevated, increasing financial risk.
Key Dynamics to Monitor
FOLD carries more volatility with a beta of 0.48 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
ALNY generates stronger free cash flow (49M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ALNY scores higher overall (65/100 vs 30/100) and 96.4% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Amicus Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing and delivering drugs for people living with rare metabolic diseases. The company is headquartered in Philadelphia, Pennsylvania.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?